FDMT - 4D Molecular Therapeutics GAAP EPS of -$0.86 misses by $0.02, revenue of $0.01M misses by $0.44M
2025-05-08 17:59:48 ET
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
- 4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment
- Cantor analysts call for RFK Jr. replacement following ousting of Marks at FDA
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics
- Historical earnings data for 4D Molecular Therapeutics